Citadel Advisors
GNLX icon

Citadel Advisors’s Genelux GNLX Stock Holding History

Citadel Advisors’s Portfolio GNLX Stock Details GNLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,300
Closed -$85.3K – 13176
2025
Q3 		$85.3K Buy
+20,300
New +$72.1K ﹤0.01% 11940
2025
Q2 		– Sell
-10,100
Closed -$27.3K – 13464
2025
Q1 		$27.3K Buy
+10,100
New +$37.9K ﹤0.01% 12903

Other funds holding GNLX

WDC
Woodward Diversified Capital Bakersfield, California $227M AUM 40.62% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's GNLX Position: Q1 2026 in Review

Citadel Advisors sold out of Genelux (GNLX) in Q1 2026, closing a stake of 19,415 shares — an estimated $84.6K sold.

Citadel Advisors first reported a position in GNLX in Q1 2023 and held it in 8 quarters. The position peaked at $294K in Q1 2023. 71 funds tracked by Wall St. Rank hold GNLX as of Q1 2026.

  • Citadel Advisors reported no remaining Genelux position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 19,415 Genelux shares in Q1 2026, an estimated $84.6K.
  • Citadel Advisors first reported a position in Genelux in Q1 2023 and held it in 8 quarters.
  • Citadel Advisors's Genelux position peaked at $294K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Genelux as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.